Trevi Therapeutics 4Q Loss Widens, Cough Treatment Trials Move Forward

Dow Jones03-19

By Katherine Hamilton

Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments.

The biopharmaceutical company posted a loss of $11.4 million, or 11 cents a share, in the three months ended Dec. 31, compared with a loss of $7.8 million, or 8 cents a share, a year earlier.

Research and development expenses increased to $9.3 million from $6.5 million the year before primarily because of increased clinical development costs for two trials and a study, as well as more expenses for personnel, Trevi said.

Full-year loss in 2024 was $47.9 million, compared with $29.1 million in 2023.

The New Haven, Conn. company did not share revenue data, in keeping with previous quarters.

Earlier this month, Trevi shares climbed after it shared positive topline results from a Phase 2a trial of Haduvio, its treatment for patients with refractory chronic cough. It also shared positive results in December for a separate trial of Haduvio.

Trevi said it completed enrollment in February for the Phase 2b Coral trial in idiopathic pulmonary fibrosis patients with chronic cough, and expects topline data in the second quarter of 2025.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 18, 2025 16:17 ET (20:17 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520934516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-19 04:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520934516","market":"sh","top_or_hot":-1,"title":"Trevi Therapeutics 4Q Loss Widens, Cough Treatment Trials Move Forward","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Trevi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments. \n</p>\n<p>\n  The biopharmaceutical company posted a loss of $11.4 million, or 11 cents a share, in the three months ended Dec. 31, compared with a loss of $7.8 million, or 8 cents a share, a year earlier. \n</p>\n<p>\n  Research and development expenses increased to $9.3 million from $6.5 million the year before primarily because of increased clinical development costs for two trials and a study, as well as more expenses for personnel, Trevi said. \n</p>\n<p>\n  Full-year loss in 2024 was $47.9 million, compared with $29.1 million in 2023. \n</p>\n<p>\n  The New Haven, Conn. company did not share revenue data, in keeping with previous quarters. \n</p>\n<p>\n  Earlier this month, Trevi shares climbed after it shared positive topline results from a Phase 2a trial of Haduvio, its treatment for patients with refractory chronic cough. It also shared positive results in December for a separate trial of Haduvio. \n</p>\n<p>\n  Trevi said it completed enrollment in February for the Phase 2b Coral trial in idiopathic pulmonary fibrosis patients with chronic cough, and expects topline data in the second quarter of 2025. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2025 16:17 ET (20:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trevi Therapeutics 4Q Loss Widens, Cough Treatment Trials Move Forward</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrevi Therapeutics 4Q Loss Widens, Cough Treatment Trials Move Forward\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-19 04:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  Trevi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments. \n</p>\n<p>\n  The biopharmaceutical company posted a loss of $11.4 million, or 11 cents a share, in the three months ended Dec. 31, compared with a loss of $7.8 million, or 8 cents a share, a year earlier. \n</p>\n<p>\n  Research and development expenses increased to $9.3 million from $6.5 million the year before primarily because of increased clinical development costs for two trials and a study, as well as more expenses for personnel, Trevi said. \n</p>\n<p>\n  Full-year loss in 2024 was $47.9 million, compared with $29.1 million in 2023. \n</p>\n<p>\n  The New Haven, Conn. company did not share revenue data, in keeping with previous quarters. \n</p>\n<p>\n  Earlier this month, Trevi shares climbed after it shared positive topline results from a Phase 2a trial of Haduvio, its treatment for patients with refractory chronic cough. It also shared positive results in December for a separate trial of Haduvio. \n</p>\n<p>\n  Trevi said it completed enrollment in February for the Phase 2b Coral trial in idiopathic pulmonary fibrosis patients with chronic cough, and expects topline data in the second quarter of 2025. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2025 16:17 ET (20:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRVI","symbol_name":"Trevi Therapeutics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2520934516","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520934516","pubTimestamp":1742329020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments.The biopharmaceutical company posted a loss of $11.4 million, or 11 cents a share, in the three months ended Dec. 31, compared with a loss of $7.8 million, or 8 cents a share, a year earlier.Research and development expenses increased to $9.3 million from $6.5 million the year before primarily because of increased clinical development costs for two trials and a study, as well as more expenses for personnel, Trevi said.Full-year loss in 2024 was $47.9 million, compared with $29.1 million in 2023.The New Haven, Conn. company did not share revenue data, in keeping with previous quarters.Earlier this month, Trevi shares climbed after it shared positive topline results from a Phase 2a trial of Haduvio, its treatment for patients with refractory chronic cough. It also shared positive results in December for a separate trial of Haduvio.Trevi said it completed enrollment","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRVI":"Trevi Therapeutics Inc.","BK4202":"服装、服饰与奢侈品","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"Trevi Therapeutics第四季度亏损扩大，咳嗽治疗试验向前推进","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"TRVI":0.9,"FORD":1},"content_text":"By Katherine Hamilton \n\n\n  Trevi Therapeutics posted a wider loss in the fourth quarter as it increased spending on trials for chronic cough treatments. \n\n\n  The biopharmaceutical company posted a loss of $11.4 million, or 11 cents a share, in the three months ended Dec. 31, compared with a loss of $7.8 million, or 8 cents a share, a year earlier. \n\n\n  Research and development expenses increased to $9.3 million from $6.5 million the year before primarily because of increased clinical development costs for two trials and a study, as well as more expenses for personnel, Trevi said. \n\n\n  Full-year loss in 2024 was $47.9 million, compared with $29.1 million in 2023. \n\n\n  The New Haven, Conn. company did not share revenue data, in keeping with previous quarters. \n\n\n  Earlier this month, Trevi shares climbed after it shared positive topline results from a Phase 2a trial of Haduvio, its treatment for patients with refractory chronic cough. It also shared positive results in December for a separate trial of Haduvio. \n\n\n  Trevi said it completed enrollment in February for the Phase 2b Coral trial in idiopathic pulmonary fibrosis patients with chronic cough, and expects topline data in the second quarter of 2025. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 16:17 ET (20:17 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520934516","isCrawlerRequest":true}